Research site

Stoke-on-Trent ST4 7LN

2 studies enrolling now · 20 studies all time

What they study most

Asthma, Breast Cancer, Breast Cancer, Early Breast Cancer, Dyslipidemia, Hormone Receptor Positive Breast Cancer, Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer, Migraine, Migraine Disorders, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer (NSCLC), Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis

Studies at this site

• A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma — Recruiting now
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations — Recruiting now
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer — Running, not enrolling
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer — Completed
• A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. — Completed
• A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer — Completed
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
• Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention — Completed
• A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. — Completed
• A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention — Completed
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) — Completed
• CLARITY Extension Study — Completed
• Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine — Completed
• Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer — Completed
• Atacicept in Multiple Sclerosis Extension Study, Phase II — Stopped early
• A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) — Stopped early
• Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) — Stopped early
• Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding. — Completed
• Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) — Stopped early